Adjuvant Capital is a life sciences investment firm specializing in global health. They focus on early to mid-stage companies, primarily investing in Series A and B rounds, with occasional participation in later stages. The firm's geographical scope is global, targeting innovations that address critical health challenges worldwide.

Notable portfolio companies include 54Gene, Antiva Biosciences, and Codagenix. Adjuvant Capital's investment philosophy centers on supporting technologies and solutions that can significantly impact global health outcomes. They likely offer strategic guidance and industry connections to their portfolio companies, leveraging their expertise in the life sciences and global health sectors.